Barclays
AXDX

Barclays’s Accelerate Diagnostics AXDX Stock Holding History

Barclays’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$58K – 7001
2018
Q4 		$58K Sell
500
-17,440
-97% -$2.58M ﹤0.01% 5392
2018
Q3 		$4.12M Buy
17,940
+3,560
+25% +$787K ﹤0.01% 2008
2018
Q2 		$3.21M Sell
14,380
-9,180
-39% -$2.05M ﹤0.01% 2115
2018
Q1 		$5.38M Buy
23,560
+13,210
+128% +$3.47M ﹤0.01% 1579
2017
Q4 		$2.71M Buy
10,350
+3,310
+47% +$776K ﹤0.01% 2160
2017
Q3 		$1.58M Buy
7,040
+5,420
+335% +$1.33M ﹤0.01% 2566
2017
Q2 		$443K Buy
+1,620
New +$439K ﹤0.01% 3645
2014
Q3 		– Sell
-8,500
Closed -$2.21M – 7649
2014
Q2 		$2.21M Hold
8,500
– – ﹤0.01% 2490
2014
Q1 		$1.78M Buy
+8,500
New +$1.26M ﹤0.01% 2653

Other funds holding AXDX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CS
Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's AXDX Position: Q4 2024 in Review

Barclays sold out of Accelerate Diagnostics (AXDX) in Q4 2024, closing a stake of 100 shares — an estimated $171 sold.

Barclays first reported a position in AXDX in Q2 2013 and held it in 36 quarters. The position peaked at $1.54M in Q2 2019. 47 funds tracked by Wall St. Rank hold AXDX as of Q4 2024.

  • Barclays reported no remaining Accelerate Diagnostics position as of Q4 2024 after selling out during the quarter.
  • Barclays sold 100 Accelerate Diagnostics shares in Q4 2024, an estimated $171.
  • Barclays first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 36 quarters.
  • Barclays's Accelerate Diagnostics position peaked at $1.54M in Q2 2019.
  • 47 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.